Home
CSTL
CSTL News

Latest Castle Biosciences Inc. (CSTL) News on October 7, 2025

Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine

GlobeNewswire

6 days ago

Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

4 months ago

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

4 months ago

Castle Biosciences, SciBase Partner to Develop Predictive Tests for Skin Conditions

Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases

GlobeNewswire

4 months ago

Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases

Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention

GlobeNewswire

4 months ago

Castle Biosciences’ Chief Executive Officer Derek Maetzold to Participate in Panel Discussion During the 2025 BIO International Convention

Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®

GlobeNewswire

4 months ago

Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®

7 Luxury Vehicles Expected To Skyrocket in Price Due To Trump’s Tariffs

GOBankingRates

4 months ago

7 Luxury Vehicles Expected To Skyrocket in Price Due To Trump’s Tariffs

3 International Vacations That Are Cheaper Than an iPhone

GOBankingRates

4 months ago

3 International Vacations That Are Cheaper Than an iPhone

Suze Orman’s 5 Best Tips for Saving Money Even When Living Paycheck to Paycheck

GOBankingRates

4 months ago

Suze Orman’s 5 Best Tips for Saving Money Even When Living Paycheck to Paycheck

This week in Trumponomics: Too bad TACO isn’t true

Yahoo Finance

4 months ago

This week in Trumponomics: Too bad TACO isn’t true

Starmer says Farage would spook the City and give us Truss 2 – he could be right

The Guardian

4 months ago

Starmer says Farage would spook the City and give us Truss 2 – he could be right

AI ecosystem isn't just Nvidia: Unlock it further with this ETF

Yahoo Finance Video

4 months ago

AI ecosystem isn't just Nvidia: Unlock it further with this ETF

Is Dave Ramsey's Home Buying Advice Realistic For The Average Homeowner?

Benzinga

4 months ago

Is Dave Ramsey's Home Buying Advice Realistic For The Average Homeowner?

Ford recalls more than 29,000 vehicles in the US, NHTSA says

Reuters

4 months ago

Ford recalls more than 29,000 vehicles in the US, NHTSA says

Castle Biosciences, Inc. (CSTL) Unveils Largest Real-World Melanoma Risk Study at ASCO 2025

Insider Monkey

4 months ago

Castle Biosciences, Inc. (CSTL) Unveils Largest Real-World Melanoma Risk Study at ASCO 2025

New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes

GlobeNewswire

4 months ago

New Data at ASCO 2025 Affirms DecisionDx®-Melanoma's Ability to Improve Upon Staging-Based Risk Stratification and Predict Survival Outcomes

Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

GlobeNewswire

5 months ago

Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference

Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result

GlobeNewswire

5 months ago

Real-World Study Confirms Long-Term Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with the DecisionDx-UM Class Result

Castle Biosciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

5 months ago

Castle Biosciences First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Castle Biosciences Celebrates Skin Cancer Awareness Month

GlobeNewswire

5 months ago

Castle Biosciences Celebrates Skin Cancer Awareness Month

Thomson Reuters StreetEvents

5 months ago

Q1 2025 Castle Biosciences Inc Earnings Call

Castle Biosciences Inc (CSTL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...

GuruFocus.com

5 months ago

Castle Biosciences Inc (CSTL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amidst ...

Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates

Zacks

5 months ago

Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates

Castle Biosciences Reports First Quarter 2025 Results

GlobeNewswire

5 months ago

Castle Biosciences Reports First Quarter 2025 Results

Castle Biosciences to Acquire Previse

GlobeNewswire

5 months ago

Castle Biosciences to Acquire Previse

New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer

GlobeNewswire

5 months ago

New Data at DDW 2025 Further Demonstrates the TissueCypher® Test's Ability to Identify Patients at Increased Risk for Developing Esophageal Cancer

Castle Biosciences Inc (CSTL) Q1 2025 Earnings Report Preview: What To Expect

GuruFocus.com

5 months ago

Castle Biosciences Inc (CSTL) Q1 2025 Earnings Report Preview: What To Expect

New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

GlobeNewswire

5 months ago

New Study Shows Castle Biosciences’ DecisionDx®-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of Sentinel Lymph Node Positivity

MT Newswires

5 months ago

Castle Biosciences' DecisionDx-Melanoma Test Orders Reach 200,000

DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma

GlobeNewswire

5 months ago

DecisionDx®-Melanoma Test Ordered More Than 200,000 Times for Patients Diagnosed with Cutaneous Melanoma

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

GlobeNewswire

5 months ago

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025

GlobeNewswire

6 months ago

Castle Biosciences to Release First Quarter 2025 Financial Results and Host Conference Call on Monday, May 5, 2025

Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships

GlobeNewswire

6 months ago

Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships

Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year

GlobeNewswire

6 months ago

Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year

Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test

GlobeNewswire

6 months ago

Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test

Are Castle Biosciences, Inc.'s (NASDAQ:CSTL) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

Simply Wall St.

6 months ago

Are Castle Biosciences, Inc.'s (NASDAQ:CSTL) Mixed Financials The Reason For Its Gloomy Performance on The Stock Market?

Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma

GlobeNewswire

6 months ago

Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma

Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups

GlobeNewswire

6 months ago

Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups

New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio

Business Wire

7 months ago

New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio

Solid Earnings Reflect Castle Biosciences' (NASDAQ:CSTL) Strength As A Business

Simply Wall St.

7 months ago

Solid Earnings Reflect Castle Biosciences' (NASDAQ:CSTL) Strength As A Business

What Is Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Doing?

Simply Wall St.

7 months ago

What Is Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Doing?

Thomson Reuters StreetEvents

7 months ago

Q4 2024 Castle Biosciences Inc Earnings Call

Castle Biosciences Inc (CSTL) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...

GuruFocus.com

7 months ago

Castle Biosciences Inc (CSTL) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ...

Castle Biosciences, Inc. (CSTL) Surpasses Q4 Earnings and Revenue Estimates

Zacks

7 months ago

Castle Biosciences, Inc. (CSTL) Surpasses Q4 Earnings and Revenue Estimates

Business Wire

7 months ago

Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results

What To Expect From Castle Biosciences Inc (CSTL) Q4 2024 Earnings

GuruFocus.com

7 months ago

What To Expect From Castle Biosciences Inc (CSTL) Q4 2024 Earnings

Castle Biosciences to Participate in Upcoming Investor Conferences

Business Wire

7 months ago

Castle Biosciences to Participate in Upcoming Investor Conferences

CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know

Zacks

7 months ago

CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know

Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth

Zacks

8 months ago

Castle Biosciences, Inc. (CSTL) Reports Next Week: Wall Street Expects Earnings Growth

Wall Street Analysts See a 50.79% Upside in Castle Biosciences (CSTL): Can the Stock Really Move This High?

Zacks

8 months ago

Wall Street Analysts See a 50.79% Upside in Castle Biosciences (CSTL): Can the Stock Really Move This High?

Business Wire

8 months ago

Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®

Surging Earnings Estimates Signal Upside for Castle Biosciences (CSTL) Stock

Zacks

8 months ago

Surging Earnings Estimates Signal Upside for Castle Biosciences (CSTL) Stock

Castle Biosciences (CSTL) Upgraded to Buy: Here's Why

Zacks

8 months ago

Castle Biosciences (CSTL) Upgraded to Buy: Here's Why

Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?

Zacks

8 months ago

Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?

Insmed's NDA for Lung Disease Drug Gets FDA's Priority Review

Zacks

8 months ago

Insmed's NDA for Lung Disease Drug Gets FDA's Priority Review

VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%

Zacks

8 months ago

VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%

Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025

Business Wire

8 months ago

Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025

Strong week for Castle Biosciences (NASDAQ:CSTL) shareholders doesn't alleviate pain of three-year loss

Simply Wall St.

8 months ago

Strong week for Castle Biosciences (NASDAQ:CSTL) shareholders doesn't alleviate pain of three-year loss

Wall Street Analysts Think Castle Biosciences (CSTL) Could Surge 51.52%: Read This Before Placing a Bet

Zacks

8 months ago

Wall Street Analysts Think Castle Biosciences (CSTL) Could Surge 51.52%: Read This Before Placing a Bet

FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication

Zacks

8 months ago

FDA Expands Label of AZN's Enhertu for New Breast Cancer Indication

PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor

Zacks

8 months ago

PFE Stock Rises on Reports of Averting Proxy Fight With Activist Investor

NVO Stock Rises as New Obesity Drug Shows Superior Weight Loss

Zacks

8 months ago

NVO Stock Rises as New Obesity Drug Shows Superior Weight Loss

4 Top-Ranked Stocks With Solid Net Profit Margins to Buy Now

Zacks

9 months ago

4 Top-Ranked Stocks With Solid Net Profit Margins to Buy Now

Castle’s Poster on DecisionDx®-SCC Selected as a "Late Breakers" Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025

Business Wire

9 months ago

Castle’s Poster on DecisionDx®-SCC Selected as a "Late Breakers" Top Five Finalist for the Akamai Award, Recognizing the Best Posters at Maui Derm Hawaii 2025

PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales

Zacks

9 months ago

PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales

Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer Study

Zacks

9 months ago

Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer Study

Business Wire

9 months ago

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Results

FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab

Zacks

9 months ago

FDA Accepts J&J's Filing for Autoimmune Disease Drug Nipocalimab

FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia

Zacks

9 months ago

FDA Accepts Agios' sNDA for Pyrukynd in Thalassemia

CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates

Zacks

9 months ago

CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates

FDA Clears PCRX's New Iovera Smart Tip for Expanded Use in Pain Relief

Zacks

9 months ago

FDA Clears PCRX's New Iovera Smart Tip for Expanded Use in Pain Relief

AbbVie Cuts 2024 EPS Guidance to Include Acquisition Costs

Zacks

9 months ago

AbbVie Cuts 2024 EPS Guidance to Include Acquisition Costs

MT Newswires

9 months ago

Sector Update: Health Care Stocks Rise in Afternoon Trading

Castle Biosciences gains New York state approval for Barrett’s oesophagus test

Medical Device Network

9 months ago

Castle Biosciences gains New York state approval for Barrett’s oesophagus test

MT Newswires

9 months ago

Castle Biosciences Says TissueCypher Test Approved by New York Health Department

Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus Test

Business Wire

9 months ago

Castle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus Test

Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

Zacks

9 months ago

Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug

Zacks

9 months ago

MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug

CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

Zacks

9 months ago

CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

Neumora Stock Hits Record Low on Depression Drug Study Failure

Zacks

9 months ago

Neumora Stock Hits Record Low on Depression Drug Study Failure

PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?

Zacks

9 months ago

PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?

MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN

Zacks

9 months ago

MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag

Zacks

9 months ago

VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag

Castle Biosciences reports preliminary data from atopic dermatitis test study

Medical Device Network

9 months ago

Castle Biosciences reports preliminary data from atopic dermatitis test study

Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek

Zacks

9 months ago

Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek

Business Wire

9 months ago

Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test

KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707

Zacks

10 months ago

KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707

SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder

Zacks

10 months ago

SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire

10 months ago

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Merck Ends Development of Two Experimental Cancer Drugs

Zacks

10 months ago

Merck Ends Development of Two Experimental Cancer Drugs

4 Solid Net Profit Margin Stocks to Boost Portfolio Returns

Zacks

10 months ago

4 Solid Net Profit Margin Stocks to Boost Portfolio Returns

CHMP Endorses Merck's Kidney Cancer Drug for Two Indications

Zacks

10 months ago

CHMP Endorses Merck's Kidney Cancer Drug for Two Indications

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

Zacks

10 months ago

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 42.02%: Here's is How to Trade

Zacks

10 months ago

Wall Street Analysts Believe Castle Biosciences (CSTL) Could Rally 42.02%: Here's is How to Trade

ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline

Zacks

10 months ago

ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline

Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday

Zacks

10 months ago

Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday

Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma

Business Wire

10 months ago

Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma

Here's Why Agios Stock Plummeted More Than 20% on Monday

Zacks

10 months ago

Here's Why Agios Stock Plummeted More Than 20% on Monday

AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal

Zacks

10 months ago

AbbVie's Recently Acquired Parkinson's Drug Meets Third Study Goal

GSK Expands Vaccine Collaboration With Zhifei in China

Zacks

10 months ago

GSK Expands Vaccine Collaboration With Zhifei in China

Share on Social Networks: